Kerstin Kenne

PhD

Role in PharmNovo: Consultant and toxicology advisor.

Company: Toxicology Knowledge Team Sweden.

Resumé: Kerstin has a PhD from Karolinska Institutet, Stockholm. Her research background is within the area of cell biology and DNA repair. She has 16 years of experience from toxicology at Safety Assessment, AstraZeneca, working as toxicology project leader and study director for in vivo toxicology studies, and within molecular toxicology. During the last 8 years she has been working at Toxicology Knowledge Team Sweden as a consultant and cofounder.

Member of:

Operational team

Latest news

View all

Reports of broader therapeutic potential for PN6047

June 29, 2026

Reports of broader therapeutic potential for PN6047

PharmNovo AB announces today new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine.

April 17, 2026

Watch PharmNovo at LSX in Lisbon

Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.

April 9, 2026

Capsules ready for Phase IIa Study

PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.

January 30, 2026

Welcome on Board

As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.